Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CANDEX vs EXELDERM
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Candesartan is an angiotensin II receptor blocker (ARB) that selectively binds to the AT1 receptor, inhibiting the vasoconstrictor and aldosterone-secreting effects of angiotensin II, leading to vasodilation and reduced blood pressure.
Topical antimycotic that inhibits fungal squalene epoxidase, leading to accumulation of squalene and disruption of fungal cell wall synthesis.
Hypertension,Heart failure (NYHA class II-IV and left ventricular systolic dysfunction, to reduce cardiovascular mortality)
Tinea pedis,Tinea cruris,Tinea corporis,Tinea versicolor
Adults: 150 mg orally once daily
Apply a thin layer to affected skin twice daily (morning and evening).
Terminal elimination half-life is 20-30 hours (mean 24 hours) in adults; prolonged in hepatic impairment (up to 50 hours) and requires dose adjustment.
Not applicable due to negligible systemic absorption; after topical application, half-life in skin is several hours.
Primarily metabolized by CYP2C9 to an inactive metabolite; also undergoes O-deethylation. Minimal hepatic metabolism, primarily excreted unchanged in bile and urine.
Minimal systemic absorption; when absorbed, primarily metabolized in the liver via oxidation and glucuronidation.
Primarily hepatic metabolism via CYP2C9, with <1% excreted unchanged in urine. Approximately 70-80% eliminated in feces as metabolites, 20-30% in urine as metabolites.
Systemic absorption is minimal; any absorbed sulconazole is primarily metabolized in the liver and excreted in feces via bile; renal excretion of unchanged drug is negligible.
99% bound to albumin (primarily), also to alpha-1-acid glycoprotein.
Not applicable; systemic levels are undetectable with topical use.
Extensive: 1.5-2 L/kg, indicating wide distribution into tissues including skin, nails, and adipose tissue. Accumulates in stratum corneum and nails.
Not applicable; negligible systemic absorption.
Oral: 99% (well absorbed); food does not affect absorption. No IV formulation due to poor water solubility; not administered topically for systemic effects.
Topical: negligible systemic bioavailability (<1%) due to poor percutaneous absorption.
Cr Cl 30-60 m L/min: 100 mg once daily; Cr Cl 15-29 m L/min: 50 mg once daily; Cr Cl <15 m L/min: 50 mg every 48 hours
No dosage adjustment required for renal impairment.
Child-Pugh A: no adjustment; Child-Pugh B: 100 mg once daily; Child-Pugh C: not recommended
No dosage adjustment required for hepatic impairment.
Not established for children <18 years of age
Safety and efficacy in pediatric patients below 12 years have not been established; see prescribing information for age-specific recommendations.
No specific adjustment required; consider renal function and potential for increased sensitivity
No specific geriatric dose adjustments; use caution due to higher risk of adverse effects from prolonged use.
Fetal toxicity: Drugs acting directly on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.
None.
Fetal toxicity,Hypotension in volume-depleted patients,Renal function impairment,Hyperkalemia,Avoid concomitant use with aliskiren in patients with diabetes
Avoid contact with eyes, nose, mouth, or other mucous membranes. Discontinue if irritation or sensitization occurs. Not for oral or ophthalmic use. Use in children under 12 years not established.
Hypersensitivity to candesartan or any component,Concomitant use with aliskiren in patients with diabetes,Pregnancy
Known hypersensitivity to sulconazole or any component of the formulation.
No significant food interactions. Grapefruit juice does not interact. Avoid salt substitutes with potassium.
None known.
Teratogenic risk profile for Candesartan (CANDEX) is based on its mechanism as an angiotensin II receptor blocker (ARB). First trimester: No increased risk of major congenital malformations from first-trimester exposure based on human data, but animal studies show fetal toxicity at high doses. Second and third trimesters: Known to cause fetal renal dysfunction, oligohydramnios, skull ossification defects, and neonatal renal failure. Use is contraindicated in pregnancy, especially after 20 weeks gestation.
Category B: No teratogenic effects in animal studies; no adequate human studies in first trimester. Avoid use in first trimester unless clearly needed.
Excretion into breast milk is unknown; limited data may be available for similar ARBs but M/P ratio is not established. Due to risk of neonatal renal effects, use during breastfeeding is not recommended, especially in preterm infants or those with renal impairment. Alternative agents preferred.
Not known if excreted in breast milk. Caution in nursing mothers; limited data. M/P ratio not available.
Pharmacokinetic changes in pregnancy (increased volume of distribution, renal blood flow) may require dose adjustments. However, due to fetotoxicity, candesartan is contraindicated in pregnancy, and no dose recommendation is provided. Alternative antihypertensives such as labetalol or nifedipine are preferred.
No dose adjustment required for topical use; insufficient data for systemic absorption changes.
Candesartan is contraindicated in pregnancy (category D). Monitor renal function and electrolytes, especially in renal artery stenosis, heart failure, or volume depletion. May cause hypotension, especially in CHF patients. Dual blockade with ACEi increases risk of hyperkalemia and renal impairment.
Apply sparingly to affected area; avoid use on mucous membranes or intertriginous areas. Discontinue if irritation occurs. Not recommended for use under occlusive dressings.
Take exactly as prescribed, usually once daily.,Avoid potassium supplements or salt substitutes containing potassium without medical advice.,If you become pregnant, stop taking and contact your doctor immediately.,May cause dizziness or lightheadedness; avoid driving until you know how you react.,Report any signs of angioedema (swelling of face, lips, throat) or fainting.,Stay hydrated, especially if experiencing diarrhea or vomiting.
Use only on the skin as directed; avoid contact with eyes, mouth, or open wounds.,Wash hands before and after applying unless treating hands.,Do not cover the treated area with bandages or wrappings unless directed by a doctor.,Stop use and consult doctor if condition worsens or does not improve within 2 weeks.,Inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CANDEX vs EXELDERM, answered by our medical review team.
CANDEX is a Topical Antifungal and Corticosteroid that works by Candesartan is an angiotensin II receptor blocker (ARB) that selectively binds to the AT1 receptor, inhibiting the vasoconstrictor and aldosterone-secreting effects of angiotensin II, leading to vasodilation and reduced blood pressure.. EXELDERM is a Topical Antifungal that works by Topical antimycotic that inhibits fungal squalene epoxidase, leading to accumulation of squalene and disruption of fungal cell wall synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CANDEX and EXELDERM depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CANDEX is: Adults: 150 mg orally once daily. The standard adult dose of EXELDERM is: Apply a thin layer to affected skin twice daily (morning and evening).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CANDEX and EXELDERM in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CANDEX is classified as Category C. Teratogenic risk profile for Candesartan (CANDEX) is based on its mechanism as an angiotensin II receptor blocker (ARB). First trimester: No increased risk of major congenital malf. EXELDERM is classified as Category C. Category B: No teratogenic effects in animal studies; no adequate human studies in first trimester. Avoid use in first trimester unless clearly needed.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.